These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30610419)

  • 1. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
    Paes B; Kim D; Saleem M; Wong S; Mitchell I; Lanctot KL;
    Eur J Pediatr; 2019 Mar; 178(3):377-385. PubMed ID: 30610419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
    Wang DY; Saleem M; Paes BA; Mitchell I; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
    Paes BA; Saleem M; Li A; Lanctôt KL; Mitchell I;
    Pediatr Infect Dis J; 2020 Jun; 39(6):539-545. PubMed ID: 32235248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
    Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
    Mitchell I; Li A; Bjornson CL; Lanctot KL; Paes BA;
    Am J Perinatol; 2022 Nov; 39(15):1668-1677. PubMed ID: 33657636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab Adherence and Outcomes in Canadian Aboriginal Children.
    Hui C; Paes B; Papenburg J; Mitchell I; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2016 Nov; 35(11):1187-1193. PubMed ID: 27331856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
    Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A; Butt ML; Dix J; Elliott L; Paes B
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab.
    Paes B; Li A; Kim D; Lanctot KL; Mitchell I;
    Am J Perinatol; 2021 Aug; 38(S 01):e129-e136. PubMed ID: 32232817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B; Mitchell I; Yi H; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2014 Feb; 33(2):e29-33. PubMed ID: 23989104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
    Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
    Rodgers-Gray BS; Fullarton JR; Carbonell-Estrany X; Keary IP; Tarride JÉ; Paes BA
    J Med Econ; 2023; 26(1):630-643. PubMed ID: 37067826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.